Takeda Pharmaceutical Company Limited Stock price

Equities

4502

JP3463000004

Pharmaceuticals

Delayed Japan Exchange 01:00:00 2023-12-05 am EST Intraday chart for Takeda Pharmaceutical Company Limited 5-day change 1st Jan Change
4,137 JPY +0.12% -1.43% +0.63%
Sales 2024 * 4,007B 27.22B Sales 2025 * 3,924B 26.65B Capitalization 6,483B 44.04B
Net income 2024 * 147B 999M Net income 2025 * 245B 1.67B EV / Sales 2024 *
2,54x
Net Debt 2024 * 3,714B 25.23B Net Debt 2025 * 3,344B 22.72B EV / Sales 2025 *
2,50x
P/E ratio 2024 *
49,0x
P/E ratio 2025 *
27,5x
Employees 49,095
Yield 2024 *
4,55%
Yield 2025 *
4,58%
Free-Float 98.15%
More Fundamentals * Assessed data
Dynamic Chart
Zhejiang Medicine Wins Nod to Trial Digestive Acid Drug MT
The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema CI
Neurocrine Reports Two Mid-Stage Trial Misses; Shares Fall MT
Takeda Announce ADZYNMA Approves by US FDA - First & Only Recombinant ADAMTS13 Enzyme Replacement Therapy for cTTP CI
U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura CI
Takeda Pharma gets FDA approval for rare blood disorder therapy RE
Takeda Gets FDA Approval For Blood-Clotting Disorder Treatment DJ
Hutchmed hails Takeda's fruquintinib approval from US for cancer form AN
Takeda Secures US FDA Clearance for Colorectal Cancer Drug Fruquintinib MT
US FDA OKs Hutchmed's Colorectal Cancer Treatment; Shares Fall 5% MT
Takeda Says FDA Approves Treatment for Colorectal Cancer DJ
Takeda Receives U.S. FDA Approval of FRUZAQLA? (fruquintinib) for Previously Treated Metastatic Colorectal Cancer CI
Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting CI
Japan Shares Rebounded on Friday; Takeda Shares Fall Over 7% Following 75% Drop in Fiscal H1 Attributable Profit MT
Japan's Nikkei rebounds, chip stocks lead recovery RE
More news
1 day-0.94%
1 week-1.69%
Current month-0.79%
1 month-0.43%
3 months-8.38%
6 months-7.52%
Current year+0.51%
More quotes
1 week
4 119.00
Extreme 4119
4 206.00
1 month
4 098.00
Extreme 4098
4 245.00
Current year
3 981.00
Extreme 3981
4 873.00
1 year
3 917.00
Extreme 3917
4 873.00
3 years
2 993.00
Extreme 2993
4 873.00
5 years
2 894.50
Extreme 2894.5
4 873.00
10 years
2 894.50
Extreme 2894.5
6 693.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 2014
Director of Finance/CFO 52 2014
Compliance Officer 53 2011
Members of the board TitleAgeSince
Director/Board Member 71 2016
Director/Board Member 62 2018
Director/Board Member 70 2018
More insiders
Date Price Change Volume
23-12-05 4,137 +0.12% 2 893 000
23-12-04 4,132 -0.94% 3,015,400
23-12-01 4,171 +0.14% 3,364,400
23-11-30 4,165 +0.85% 5,667,000
23-11-29 4,130 -1.60% 3,795,500

Delayed Quote Japan Exchange, December 04, 2023 at 01:00 am EST

More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
4,132JPY
Average target price
4,724.74JPY
Spread / Average Target
+14.35%
Consensus
1st Jan change Capi.
+0.51% 44 448 M $
+60.09% 525 B $
+47.59% 454 B $
-10.06% 381 B $
-5.31% 262 B $
-10.80% 253 B $
-15.22% 221 B $
+3.05% 202 B $
-8.49% 200 B $
-42.86% 163 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Takeda Pharmaceutical Company Limited - Japan Exchange
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer